Background and objectives Disseminated intravascular coagulation (DIC) is common in deceased kidney donors and is considered a relative contraindication to donation. The significance of donor DIC on recipient kidney function is poorly understood. Additionally, the significance of thrombocytopenia in recipients of kidneys from DIC-positive donors is understudied.
Introduction
The number of potential recipients of kidney transplants far outstrips the number of organs available for transplantation (1). To narrow this disparity, strategies have been implemented to expand the deceased-donor pool (2), but additional approaches could be considered. One such potential approach is the use of organs from donors with disseminated intravascular coagulation (DIC). Characterized by formation of intravascular fibrin, DIC, which results in thrombotic occlusion of small and midsized vessels (3) and which can prompt multiorgan failure, has traditionally been considered by many to be a strong relative contraindication to kidney donation (4 -11), probably because of empirical observations of poor graft outcomes (12) . Therefore, utilization of kidneys from DIC-positive (DIC(ϩ)) donors remains controversial. However, some recent case reports (9,10) and a case series (7) have described favorable outcomes utilizing kidneys from DIC(ϩ) donors. Because donor DIC is relatively common, being present in as many as 29% of deceased organ donors (13) , an understanding of the suitability of organ transplantation from DIC(ϩ) donors has potentially important implications.
An associated question is the clinical significance of thrombocytopenia in individuals receiving DIC(ϩ) donor kidneys. We have noted a disproportionately high rate of posttransplant thrombocytopenia in recipients of kidneys from DIC(ϩ) donors, an observation also made by others (9,10). This observation has a plausible mechanistic explanation because the decrease in platelets in the setting of DIC is a result of ongoing thrombosis and consumption of platelets (14, 15) . Thus, recipient thrombocytopenia could signal processes such as ongoing thrombosis and activation of coagulation attributable to the presence of a focus of DIC (i.e., the donor kidney). Whether recipient thrombocytopenia might be a marker of ongoing thrombosis in the donor kidney that adversely affects graft function has not been systematically studied.
Because study of the effects of donor DIC on recipient outcomes is lacking, we assembled a single-center retrospective cohort of 162 kidney transplant recipients. Using strictly specified criteria for the selection of DIC(ϩ) donors, we sought to determine whether the presence of DIC in kidney donors, independent of traditional risk factors, is associated with delayed or slow graft function after transplantation. Additionally, we examined whether the presence of low platelets immediately after organ implantation in recipients of kidneys procured from DIC(ϩ) donors is associated with poor outcomes.
Materials and Methods

Participants
The participants consisted of a retrospective cohort of all 162 consecutive recipients of deceased-donor renal allografts (in the form of kidney transplants alone or simultaneous pancreas-kidney [SPK] transplants) at a single center between May 1, 2007 (the start of the United Network for Organ Sharing electronic donor notification system known as "Donornet") and December 31, 2008 . We included SPK recipients because our center makes little distinction in allocating kidneys to SPK recipients on the basis of donor DIC. The institutional review board, in accordance with the principles of the Declarations of Helsinki, approved this study.
Experimental Design and Associated Definitions
Information on recipients (demographics, medical histories, laboratory values, operative characteristics, immunosuppressive regimens [protocols for which are shown in Supplementary Table 1] , and outcomes of interest) was collected. Relevant information on the donors was obtained from Donornet.
Definitions were established for DIC (in the donor), thrombocytopenia (in the recipient), and the combined outcome of delayed plus slow graft function of the allograft. Diagnostic criteria for DIC required a DIC score at least 4 based on a system proposed by the International Society of Thrombosis and Hemostasis (16), a system commonly used in transplantation (13, 17, 18) . Diagnosis of donor DIC was made if three or more of the following clinical criteria were met: peak protime Ͼ 15 seconds, peak activated partial prothromboplastin time Ͼ 50 seconds, platelet count nadir Ͻ 150,000/ml (the lower limit of normal in our laboratory), fibrinogen nadir Ͻ 100 mg/dl and/or D-dimer peak Ͼ 1000 mg/L. Potential DIC(ϩ) donors were excluded if any of the following criteria were met: age Ն 60 years or Յ3 years, extended criteria donor (ECD) status, cold ischemia time (CIT) Ն 36 hours, terminal creatinine (Cr) Ͼ 3.0 mg/dl, glomerular sclerosis Ն 10% (if biopsied), blood flow Յ 90 ml/min, or resistance Ն 0.4 mmHg/ml per minute (if placed on a pulsatile perfusion machine). There was no lower weight limit for adult donors (although Ͻ5% of the donors weigh Ͻ60 kg), whereas for pediatric donors Ͼ3 years, weight had to exceed 10 kg. Kidneys were eligible for machine perfusion if donors had one or more of the following criteria: ECD or donation after cardiac death (DCD) status; CIT Ͼ 30 hours; Cr Ͼ 2.0 mg/dl; and/or history of hypertension, diabetes, or kidney disease. Presence of DIC in the donor alone was not an indication for machine perfusion.
Thrombocytopenia was defined as (1) onset within 4 days posttransplant if platelet count was Ͻ150,000/ml, or (2) a 50% reduction in baseline platelet count within 4 days posttransplant if the pretransplant platelet count was Ͻ150,000/ml. The attribution of thrombocytopenia was made whether or not the patient received thromboglobulin (see below). Delayed graft function (DGF) was defined a need for dialysis (hemodialysis in all patients) within 7 days posttransplant, whereas slow graft function (SGF) was defined as serum Cr Ն3.0 mg/dl on posttransplant day 5 (19) . Hemodialysis, used relatively infrequently at our center, was initiated based on prespecified criteria (listed in Supplementary Table 2).
Statistical Analyses
Two-sided t tests were used to describe continuous variables and 2 tests for dichotomous variables. Univariate and multivariate logistic regression modeling was undertaken to analyze the potential effect of DGF risk factors, including donor DIC status, on the primary outcome (combined DGF plus SGF). Because the rate of ECDs and DCDs differed between recipients of DIC(ϩ) and DIC-negative (DIC(-)) kidneys, a sensitivity analysis was performed in which all recipients of ECD/DCD kidneys were eliminated. To model the independent effect of posttransplant thrombocytopenia on outcome in recipients of DIC(ϩ) donor kidneys, univariate and multivariate modeling was again used. In recipients of DIC(ϩ) donor kidneys, a sensitivity analysis was undertaken in which the rate of thrombocytopenia in recipients of DIC(ϩ) donor kidneys was "operationally" reduced by subtracting the background rate of thrombocytopenia (determined by an analysis of the rate of thrombocytopenia in the DIC(-) cohort) to determine the theoretical risk of DGF/SGF associated with "thrombocytopenia attributable only to DIC(ϩ) donor status." A final analysis was undertaken to determine whether thrombocytopenia was associated with DGF/SGF only in the recipients of DIC(-) donor kidneys. All analyses used SAS version 9.1 (SAS Institute, Cary, NC); a P value of 0.05 was considered as statistically significant.
Results
Baseline characteristics of the recipients are shown in Table 1 . The rate of ECD and DCD kidneys varied significantly between groups because the simultaneous presence of donor DIC and either ECD or DCD status is a relative contraindication to transplantation at our center. Donor characteristics were examined by DIC status; platelet count (75,000 Ϯ 67,000/ml versus 174,000 Ϯ 99,000/ml, P Ͻ 0.0001) and PTT (89 Ϯ 86 seconds versus 34 Ϯ 11 seconds, P ϭ 0.0001) were different in DIC(ϩ) and DIC(-) donors, respectively. Final Cr was higher (1.2 Ϯ 0.7 mg/dl versus 1.0 Ϯ 0.4 mg/dl, P ϭ 0.01) and donor age was younger (24.9 Ϯ 14.2 versus 35.5 Ϯ 17.1, P Ͻ 0.001) in the DIC(ϩ) group. As expected, head trauma as a cause of death was significantly higher in the DIC(ϩ) than in the DIC(-) donors (70.5% versus 48.3%, P ϭ 0.014), whereas no DIC(ϩ) donor had hypertension or diabetes. Rate of machine perfusion was similar between the DIC(ϩ) and DIC(-) groups (18.2% versus 28.0%, P ϭ 0.23) and between thrombocytopenia and nonthrombocytopenia recipients of kidneys from DIC(ϩ) donors (12.5% versus 21.4%, P ϭ 0.70).
Unadjusted outcomes are shown in Figure 1A through 1D. Recipients of DIC(ϩ) donor kidneys fared no worse than their DIC(-) counterparts in the rate of DGF/SGF (31.8% versus 29.7%, P ϭ 0.79), Cr at discharge (1.6 Ϯ 0.7 mg/dl versus 1.8 Ϯ 0.9 mg/dl, P ϭ 0.19), or length of hospital stay (10.5 Ϯ 5.4 days versus 12.2 Ϯ 14.6 days, P ϭ 0.26). Patient survival rate (100% versus 96.6%, P ϭ 0.56) and graft survival rate (97.7% versus 90.7%, P ϭ 0.18) at 1 year showed no difference between DIC(ϩ) and DIC(-) groups, respectively. As shown in Table 2 , univariate analysis demonstrated that although DIC(ϩ) donor status was not associated with occurrence of DGF/SGF, CIT Ͼ 24 hours, male gender, and history of previous transplant were. Multivariate modeling in which DIC(ϩ) donor status was forced into the model failed to demonstrate an inde- pendent association of DIC status with DGF/SGF; only CIT Ͼ 24 hours remained significant (P ϭ 0.008). Because ECD/DCD donors were differentially distributed among recipients of DIC(ϩ) and DIC(-) donor kidneys, a sensitivity analysis was performed in which all recipients of kidneys from ECD/DCD donors were excluded; there was still no evidence of an association of DIC donor status with DGF/SGF (P ϭ 0.88, data not shown).
The presence of thrombocytopenia by DIC donor status was examined. Individuals who experienced thrombocytopenia showed a decrease in platelets from 196,000 Ϯ 40,000 to 96,000 Ϯ 26,000, a drop of 51.1%. The results are shown in Figure 1E . Thrombocytopenia was significantly more common in recipients of kidneys from DIC(ϩ) donors (36.4% versus 16.9%, P ϭ 0.008). No statistical significant difference was observed in the rate of recipient thymoglobulin use before postoperative day (POD) 4 between the DIC(ϩ) and DIC(-) groups (38.6% versus 51.7%, P ϭ 0.16).
Because three recipients in the DIC(-) donor group developed thrombocytopenia a mean of 1.8 days after thymoglobulin, they were recoded as having thrombocytopenia for a sensitivity analysis designed to test the robustness of our findings (no recipients in the DIC(ϩ) donor group developed thrombocytopenia before thymoglobulin was given). A significant difference between rates of thrombocytopenia persisted (36.4% in the DIC(ϩ) group versus 19.5% in the DIC(-) group, P ϭ 0.02).
Additionally, we also specifically investigated whether thymoglobulin or heparin prescribed before POD 4 could confound the association between donor DIC status and thrombocytopenia. Overall, neither thymoglobulin or heparin use before POD 4 differed by donor DIC status: 38.6% of recipients in the DIC(ϩ) group received thymoglobulin versus 51.7% from the DIC(-) group (P ϭ 0.16), whereas 18.2% of recipients from DIC(ϩ) donors received heparin versus 11.9% of those from DIC(-) donors (P ϭ 0.31). Also, use of thymoglobulin was not associated with plasmin renin activity (PRA) status (P ϭ 0.62 for PRA Ͻ 30% versus Ն30%). Examined in another way, thymoglobulin was used in 45.5% of recipients from the DIC(ϩ) group with thrombocytopenia and 56.3% of those from the DIC(-) group with thrombocytopenia (P ϭ 0.74), whereas heparin was used in 12.5% of recipients from DIC(ϩ) donors with thrombocytopenia and 10.0% of recipients from DIC(-) donors with thrombocytopenia (P ϭ 1.0).
The subset of 44 individuals who received DIC(ϩ) donor kidneys was stratified according to thrombocytopenia status. Baseline characteristics, including traditional risk factors associated with DGF/SGF, are shown in Table 3 . There were no significant differences in any variable examined. 2Plt represents thrombocytopenia, defined as platelet count Ͻ150,000/ml or a 50% decrease from baseline when baseline count was Ͻ150,000/ml. Plt, platelets. a Data shown as mean Ϯ standard deviation.
Key graft and patient outcomes were examined in the recipients of DIC(ϩ) donor kidneys, as shown in Figure 2 . In unadjusted analysis, recipients who developed thrombocytopenia had significantly higher rates of DGF/SGF than those who did not (56.3% versus 17.9%, P ϭ 0.009), higher serum Cr level at discharge (1.9 Ϯ 0.7 mg/dl versus 1.5 Ϯ 0.6 mg/dl; P ϭ 0.041), and longer hospital stays (13.3 Ϯ 6.1 days versus 8.9 Ϯ 4.3 days; P ϭ 0.017). However, patient survival rate (100% in both groups) and graft survival rate (100% versus 96.4%, P ϭ 1.00) at 1 year showed no difference between groups.
In the recipients of kidneys from DIC(ϩ) donors, we determined whether thrombocytopenia or other factors were independently associated with DGF/SGF. As shown in Table 4 23 .56, P ϭ 0.012). In multivariate modeling, PRA status was marginally associated with outcome (P ϭ 0.05), whereas thrombocytopenia was strongly associated with DGF/SGF (OR 9.43, 95% CI 2.17 to 52.53, P Ͻ 0.005).
Because thrombocytopenia, a common clinical occurrence, had a baseline rate of 16.9% even in recipients of DIC(-) donor kidneys, all instances of thrombocytopenia in recipients of DIC(ϩ) donor kidneys might not be appropriately attributed to DIC in donors. We performed a sensitivity analysis in which approximately 19% (the nearest integer percentage to 16.9%) of thrombocytopenic patients were manually "reassigned" to nonthrombocytopenia 
Discussion
We demonstrate that use of a kidney from DIC(ϩ) a donor does not appear to be associated with an increased risk of DGF/SGF, nor with 1-year patient or graft survival. However, we found that thrombocytopenia in recipients of kidneys from DIC(ϩ) donors was associated with DGF/ SGF. Our findings were bolstered by several sensitivity analyses designed to test the robustness of our findings by varying clinical assumptions.
Previous case reports and series (5-10,12,13,20 -22) have presented an ominous picture: nearly half of transplanted DIC(ϩ) kidneys did not achieve immediate graft function. Older data from organ procurement organizations revealed that 41% of transplant centers would not even consider organs from donors with DIC (4); these findings are concordant with our anecdotal experiences and those garnered from colleagues at several other centers. These reports may be responsible for the traditional hesitancy among the transplant community to utilize kidneys from DIC(ϩ) donors.
However, two important studies suggest that the association of donor DIC with outcomes may be more complex than initially appreciated. Hefty et al., who utilized clinical criteria to diagnose DIC, reported that DIC donor status was not associated with DGF (13), whereas McCall et al., who utilized rigorous donor biopsy criteria to report the presence of thrombus in donor kidneys, showed that although donor DIC was associated with an increased rate of DGF, it did not affect long-term outcomes (22) . This may be because the recipient fibrinolytic system has the potential to rapidly lyse the clot present once the organ is placed (5, 6, 23, 24) . Biopsy appears to an imperfect method to guide organ allocation in this setting because of (1) false-negative results (because of the more time-sensitive, but nonspecific, staining techniques generally used in this situation) (20, (25) (26) (27) , (2) false-positive presence of fibrin thrombi resulting from foreign particles introduced during organ handling and storage (in which case the thrombi may have no deleterious effects) (28) , and (3) the inability of biopsy to predict the reversibility of fibrin by the glomerular fibrinolytic system after transplantation (29 -32) . As such, biopsy findings have not been validated by clinical outcomes.
The paper presented here differs from many of the previous contributions in several ways. This study was undertaken from the perspective of the recipient, rather than from that of the donor, and it was much larger than previous studies; as such, various factors traditionally associated with DGF or SGF could be analyzed. Previous studies in which the donor status was established as the starting point of the investigation (13, 22) did not take into account clinical risk factors in recipients, factors that, if concealed, are likely to confound the exposure-outcome relationship. Second, as a single-center study, variation in treatment is unlikely to substantially influence outcomes, unlike in other studies (13) .
In our study, we did not find that some traditional DGF risk factors (e.g., kidneys from DCD or ECD donors and older recipient age) were associated with poorer graft outcomes. However, some other studies report similar findings. Locke et al. found that DGF rate was comparable between kidneys from DCDs and from SCDs if DCD donor age was Յ50 years old and CIT was Յ12 hours (33); the mean age of our DCD donors was only 34.9 years old, whereas CIT was a modest 14.9 hours. In another study, when ECD grafts were carefully allocated to selected recipients with lower immunological risk and functional need, clinical outcomes were no worse than for kidneys from SCDs (34, 35) . Finally, several studies (36) appeared to demonstrate that age itself was not a risk factor for DGF, as did the prospective Neoral-MOST (Multinational Observational Study in renal Transplantation) of 3655 individuals (37) . Collectively, these results may explain why we did not find independent associations of DCD status, ECD status, and recipient age with suboptimal renal function.
We also investigated whether thrombocytopenia in the recipients of kidneys from DIC(ϩ) donors occurs more frequently and if it heralds DGF/SGF. A DIC(ϩ) kidney presumably contains microthrombi, providing an exogenous source of fibrin. Because an early drop of recipient platelet count was noted to be the only sign suggesting ongoing thrombotic processes during DIC (14, 38) , recipient thrombocytopenia may be the early signal for intrarenal clotting events, thereby contributing to poorer graft function. We indeed found evidence that thrombocytopenia, which occurs much more frequently in DIC(ϩ) donor kidneys, is associated with DGF/SGF, a finding that was preserved even when we attenuated the rate of thrombocytopenia in DIC(ϩ) kidney recipients by subtracting a "background" rate of thrombocytopenia.
We did consider the possibility that drugs such as valgancyclovir, mycophenolate mofetil, heparin, and thymoglobulin (the only lymphocyte-depleting agent used in our study) caused thrombocytopenia. However, we required that thrombocytopenia develop within 4 days of transplantation. Valganciclovir was not given to any patient before day 4, whereas mycophenolate mofetil is unlikely to be responsible for our between-group findings because it is prescribed universally. Heparin and thymoglobulin exposure were not statistically different by DIC or thrombocytopenia status; additionally, in the DIC(ϩ) group, thrombocytopenia developed before thymoglobulin was given.
We acknowledge several limitations to our study. First, our sample size, although larger than that of most reports, was modest. Second, because we rarely utilize DIC(ϩ) kidneys from donors with other risk factors, our findings cannot be generalized to all donors and may only be applicable in an environment in which the DIC(ϩ) donors are younger, have a high incidence of head trauma, and have negligible rates of hypertension and diabetes. We also elected to create a combined outcome measure, namely DGF plus SGF. This was done for several reasons. First, any function other than normal (immediate) function is suboptimal, and SGF is associated with poorer long-term outcome in its own right (19) . Second, at our institution, clinical criteria for dialysis initiation are relatively stringent; the practical implication of this is that many individuals who might be classified as DGF at other institutions are classified as SGF at ours. Thus, to reduce possible misclassification bias, we combined SGF with DGF. Finally, it is conceivable that machine perfusion criteria could have a bearing on graft function. However, the criteria at our organ bank are fairly standard, and because the rate of perfusion was not significantly different between DIC(ϩ) and DIC(-) donors, it is unlikely that perfusion practices substantially influenced our findings.
In summary, we demonstrate that there is no evidence of an independent association of donor DIC status with graft outcome. If our results are borne out in future long-term prospective studies, the traditional hesitancy of clinicians to use kidneys from DIC(ϩ) donors might warrant reexamination. We also show that thrombocytopenia in the setting of receipt of a kidney from a DIC(ϩ) donor appears to be an independent risk factor for suboptimal graft function. Such a clinical event in the absence of other causes of thrombocytopenia may provide an early signal prompting changes in clinical management, such as risk-stratifying individuals at risk for DGF/SGF and perhaps modifying care by administering dialysis in a timely fashion or by delaying the introduction of calcineurin inhibitors. These prospects should be the subject of future studies.
